{"gene":"AREL1","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2013,"finding":"AREL1 is a cytosolic HECT-family E3 ubiquitin ligase that interacts with and ubiquitinates IAP antagonists SMAC, HtrA2, and ARTS specifically after their release from mitochondria into the cytosol upon apoptotic stimulation, promoting their degradation and thereby inhibiting apoptosis.","method":"Co-immunoprecipitation, ubiquitination assays, knockdown/overexpression with apoptosis readouts (caspase-3 cleavage, XIAP degradation), subcellular fractionation/localization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, functional ubiquitination assays, loss-of-function rescue with defined apoptosis readouts; original discovery paper","pmids":["23479728"],"is_preprint":false},{"year":2015,"finding":"AREL1 preferentially assembles K33- and K11-linked polyubiquitin chains in vitro, enabling large-scale production of K33-linked chains when combined with linkage-selective DUBs.","method":"In vitro ubiquitin chain assembly assay, mass spectrometry linkage analysis, combination with linkage-selective deubiquitinases","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with biochemical characterization; replicated in concurrent independent study (PMID:25752577)","pmids":["25723849","25752577"],"is_preprint":false},{"year":2015,"finding":"AREL1 assembles K11/K33-linked polyubiquitin chains, while the related HECT E3 UBE3C assembles K48/K29-linked chains; K29- and K33-linked chains adopt open/dynamic and distinct conformations respectively.","method":"In vitro ubiquitin chain assembly, mass spectrometry, NMR solution studies, crystal structure of K33-linked diUb","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution, structural analysis, replicated by PMID:25723849","pmids":["25752577"],"is_preprint":false},{"year":2019,"finding":"The crystal structure of the extended HECT domain of AREL1 (aa 436–823) at 2.4 Å reveals an inverted T-shaped bilobed conformation with a unique loop (aa 567–573) absent in other HECT members; the N-terminal extended region (aa 436–482) preceding the HECT domain is essential for stability and catalytic activity. AREL1 ubiquitinates SMAC primarily on Lys62 and Lys191, and assembles K33-, K48-, and K63-linked polyubiquitin chains. E701A substitution increases auto- and SMAC-ubiquitination activity, while deletion of the C-terminal three residues abolishes autoubiquitination and reduces SMAC ubiquitination.","method":"X-ray crystallography (2.4 Å HECT domain; 2.8 Å tetrameric SMAC), in vitro ubiquitination assay, active-site mutagenesis, ubiquitin variant inhibitor","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structures plus in vitro reconstitution and mutagenesis in single study","pmids":["31732561"],"is_preprint":false},{"year":2021,"finding":"AREL1 interacts with Metaxin 2 (MTX2) via the carboxyl-terminal domain of MTX2, ubiquitinates MTX2, and promotes its degradation, thereby inhibiting TNF-induced necroptosis; the catalytically dead AREL1-C790A mutant fails to degrade MTX2.","method":"Co-immunoprecipitation (domain mapping), overexpression/knockdown, catalytic mutant (C790A), necroptosis assay","journal":"Experimental and therapeutic medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP with domain mapping and catalytic mutant, single lab","pmids":["34584540"],"is_preprint":false},{"year":2023,"finding":"AREL1, together with TRIP12, adds destabilizing K27-, K29-, and K33-linked polyubiquitin chains onto pro-IL-1β, promoting its proteasomal disposal and thereby limiting mature IL-1β production and neutrophilic inflammation; UBE2L3 acts as the cognate E2 enzyme in this process.","method":"Unbiased RNAi screen, in vivo Ube2l3 knockout mouse model, ubiquitin linkage analysis, macrophage pro-IL-1β turnover assay, inflammasome activation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — unbiased RNAi screen identifying AREL1, in vivo KO model, linkage-specific ubiquitination characterization; multiple orthogonal methods","pmids":["37474493"],"is_preprint":false},{"year":2023,"finding":"AREL1 interacts with SMAC in TGF-β-treated HUVECs and its overexpression inhibits TGF-β-induced apoptosis by downregulating SMAC, suppressing caspase-3 and caspase-9 activation; miR-320b negatively regulates AREL1 expression.","method":"Co-immunoprecipitation, overexpression, caspase activity assay, miRNA mimics/inhibitors","journal":"Journal of biochemical and molecular toxicology","confidence":"Medium","confidence_rationale":"Tier 3 — single Co-IP with functional OE data, single lab","pmids":["37522329"],"is_preprint":false},{"year":2025,"finding":"AREL1, localized to the ER, establishes membrane contacts with lysosomes by directly binding the Voa subunit of V-ATPase and catalyzes K33-linked polyubiquitylation of the V-ATPase V1B2 subunit, inducing its interaction with UBAC2 at the perinuclear ER, thereby promoting perinuclear lysosome positioning. Loss of AREL1 increases peripheral lysosomes with partially assembled V-ATPase, elevated luminal pH, and reduced degradative capacity; Arel1-knockout mice exhibit age-dependent Purkinje cell loss, ataxia, and lipofuscin accumulation indicating lysosomal dysfunction.","method":"Co-IP (Voa binding), in vitro/cell-based K33-ubiquitination assay, live-cell imaging (lysosome positioning), lysosomal pH measurement, Arel1-/- knockout mouse with behavioral/histological phenotyping, ZRANB1 (DUB) epistasis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including direct interaction, ubiquitination assay, live imaging, in vivo knockout, DUB epistasis in single rigorous study","pmids":["41331534"],"is_preprint":false}],"current_model":"AREL1 is an ER-resident HECT E3 ubiquitin ligase that preferentially assembles atypical K11-, K33-linked (and also K27-, K29-) polyubiquitin chains on substrates including IAP antagonists (SMAC, HtrA2, ARTS), MTX2, pro-IL-1β, and the V-ATPase V1B2 subunit, functioning as an anti-apoptotic and anti-necroptotic regulator, a limiter of IL-1β-driven inflammation, and a controller of perinuclear lysosome positioning and acidification through an AREL1–UBAC2–V-ATPase axis, with loss of AREL1 in mice causing lysosomal dysfunction and Purkinje cell neurodegeneration."},"narrative":{"teleology":[{"year":2013,"claim":"Establishing AREL1 as a HECT E3 ligase with anti-apoptotic function resolved how cytosolic IAP antagonists (SMAC, HtrA2, ARTS) are cleared after mitochondrial release, identifying a previously unknown ubiquitin-dependent brake on apoptosis.","evidence":"Co-immunoprecipitation, ubiquitination assays, knockdown/overexpression with caspase-3 and XIAP readouts in mammalian cells","pmids":["23479728"],"confidence":"High","gaps":["Ubiquitin chain linkage specificity on substrates was not determined","In vivo physiological relevance of AREL1-mediated IAP antagonist degradation was not tested","Structural basis for substrate recognition was unknown"]},{"year":2015,"claim":"Defining AREL1's preference for K33- and K11-linked polyubiquitin chains in vitro placed it among the rare E3 ligases generating atypical ubiquitin linkages, raising questions about the signaling roles of these chains beyond canonical proteasomal targeting.","evidence":"In vitro chain assembly, mass spectrometry linkage quantification, NMR solution studies, and crystal structure of K33-linked diUb by two independent laboratories","pmids":["25723849","25752577"],"confidence":"High","gaps":["Whether K33/K11 linkage preference holds on physiological substrates in cells was untested","No reader/decoder protein for K33-linked chains was identified","Structural basis of AREL1 HECT domain linkage selectivity was unresolved"]},{"year":2019,"claim":"The crystal structure of AREL1's extended HECT domain revealed an inverted T-shaped architecture with a unique loop and showed that N-terminal extension and C-terminal integrity are required for catalysis, providing the first structural framework for understanding its activity and regulation.","evidence":"X-ray crystallography at 2.4 Å, site-directed mutagenesis (E701A, C-terminal deletion), in vitro ubiquitination of SMAC with mapped sites (K62, K191)","pmids":["31732561"],"confidence":"High","gaps":["Structure of AREL1 bound to substrate or E2 was not obtained","Mechanism by which the unique loop (aa 567–573) contributes to function was unclear","Chain linkage selectivity determinants were not structurally resolved"]},{"year":2021,"claim":"Demonstrating that AREL1 ubiquitinates and degrades Metaxin 2 to inhibit TNF-induced necroptosis expanded its functional scope beyond apoptosis to a second cell-death modality.","evidence":"Co-immunoprecipitation with domain mapping, catalytic-dead C790A mutant, necroptosis assay in mammalian cells","pmids":["34584540"],"confidence":"Medium","gaps":["Single-laboratory finding without independent replication","Ubiquitin chain type on MTX2 was not characterized","In vivo relevance of AREL1–MTX2 axis in necroptotic disease was not tested"]},{"year":2023,"claim":"An unbiased RNAi screen identified AREL1 (with TRIP12 and the E2 UBE2L3) as a key ubiquitin ligase attaching K27/K29/K33-linked chains to pro-IL-1β, revealing a ubiquitin-dependent mechanism that limits inflammasome-driven inflammation independently of cell death.","evidence":"Genome-wide RNAi screen, Ube2l3 knockout mouse, ubiquitin linkage mass spectrometry, macrophage pro-IL-1β turnover and inflammasome activation assays","pmids":["37474493"],"confidence":"High","gaps":["Relative contributions of AREL1 versus TRIP12 to pro-IL-1β turnover were not fully dissected","Whether K33-linked chains are decoded by a specific ubiquitin-binding domain protein for pro-IL-1β disposal was unknown","Tissue-specific roles in inflammation in vivo were not resolved"]},{"year":2025,"claim":"Localizing AREL1 to the ER and showing it forms ER–lysosome contacts via V-ATPase Voa binding and K33-ubiquitylates V1B2 to recruit UBAC2 for perinuclear lysosome positioning fundamentally reframed AREL1 as a spatial organizer of lysosomal function, with knockout mice exhibiting Purkinje cell neurodegeneration and lysosomal dysfunction.","evidence":"Co-IP of Voa interaction, in vitro and cell-based K33-ubiquitination assays, live-cell lysosome imaging, pH measurements, Arel1−/− mouse behavioral/histological phenotyping, ZRANB1 DUB epistasis","pmids":["41331534"],"confidence":"High","gaps":["Whether the lysosomal phenotype fully explains the neurodegeneration or other substrates contribute was not resolved","Human genetic disease association has not been established","Structural basis of AREL1–Voa interaction at ER–lysosome contacts is unknown"]},{"year":null,"claim":"How AREL1's diverse substrate activities—anti-apoptotic IAP antagonist degradation, anti-necroptotic MTX2 degradation, pro-IL-1β disposal, and V-ATPase-dependent lysosome positioning—are coordinated in different cellular contexts, and whether K33-linked chains serve as a unifying signal decoded by specific reader proteins, remain open.","evidence":"","pmids":[],"confidence":"Low","gaps":["No K33-chain reader/decoder protein has been definitively identified beyond UBAC2","Tissue- and stimulus-specific regulation of AREL1 substrate selection is unknown","Full-length AREL1 structure with substrate and E2 has not been determined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,2,3,4,5,7]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[0,1,3,5,7]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,4,6]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1,3,5,7]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[7]}],"complexes":[],"partners":["DIABLO","HTRA2","ARTS","MTX2","TRIP12","UBE2L3","ATP6V1B2","UBAC2"],"other_free_text":[]},"mechanistic_narrative":"AREL1 is a HECT-family E3 ubiquitin ligase that assembles atypical polyubiquitin chains—predominantly K33- and K11-linked, but also K27-, K29-, K48-, and K63-linked—to regulate apoptosis, necroptosis, inflammation, and lysosomal homeostasis [PMID:25723849, PMID:25752577, PMID:31732561]. AREL1 ubiquitinates and promotes proteasomal degradation of the mitochondrial IAP antagonists SMAC, HtrA2, and ARTS following their cytosolic release during apoptosis, thereby suppressing caspase activation and cell death; it similarly ubiquitinates Metaxin 2 to inhibit TNF-induced necroptosis and cooperates with TRIP12 and the E2 UBE2L3 to attach K27/K29/K33-linked chains to pro-IL-1β, limiting inflammasome-driven inflammation [PMID:23479728, PMID:34584540, PMID:37474493]. Localized to the endoplasmic reticulum, AREL1 directly binds the V-ATPase Voa subunit and catalyzes K33-linked polyubiquitylation of the V1B2 subunit, which recruits UBAC2 at perinuclear ER–lysosome contact sites to control lysosome positioning and acidification; Arel1-knockout mice develop age-dependent Purkinje cell neurodegeneration, ataxia, and lipofuscin accumulation consistent with lysosomal dysfunction [PMID:41331534]."},"prefetch_data":{"uniprot":{"accession":"O15033","full_name":"Apoptosis-resistant E3 ubiquitin protein ligase 1","aliases":["Apoptosis-resistant HECT-type E3 ubiquitin transferase 1"],"length_aa":823,"mass_kda":94.2,"function":"E3 ubiquitin-protein ligase that catalyzes 'Lys-11'- or 'Lys-33'-linked polyubiquitin chains, with some preference for 'Lys-33' linkages (PubMed:25752577). E3 ubiquitin-protein ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:23479728, PubMed:31578312). Ubiquitinates SEPTIN4, DIABLO/SMAC and HTRA2 in vitro (PubMed:23479728). Modulates pulmonary inflammation by targeting SOCS2 for ubiquitination and subsequent degradation by the proteasome (PubMed:31578312)","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/O15033/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AREL1","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AREL1","total_profiled":1310},"omim":[{"mim_id":"615380","title":"APOPTOSIS-RESISTANT E3 UBIQUITIN PROTEIN LIGASE 1; AREL1","url":"https://www.omim.org/entry/615380"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/AREL1"},"hgnc":{"alias_symbol":["FIEL1"],"prev_symbol":["KIAA0317"]},"alphafold":{"accession":"O15033","domains":[{"cath_id":"2.60.40.10","chopping":"56-158","consensus_level":"high","plddt":88.4776,"start":56,"end":158},{"cath_id":"2.60.40.10","chopping":"166-276","consensus_level":"high","plddt":87.3723,"start":166,"end":276},{"cath_id":"2.30.29.30","chopping":"280-306_348-432","consensus_level":"high","plddt":87.3884,"start":280,"end":432},{"cath_id":"3.90.1750.10","chopping":"452-617_653-701","consensus_level":"high","plddt":89.9386,"start":452,"end":701},{"cath_id":"3.30.2410.10","chopping":"708-815","consensus_level":"high","plddt":85.5599,"start":708,"end":815}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15033","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15033-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15033-F1-predicted_aligned_error_v6.png","plddt_mean":83.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AREL1","jax_strain_url":"https://www.jax.org/strain/search?query=AREL1"},"sequence":{"accession":"O15033","fasta_url":"https://rest.uniprot.org/uniprotkb/O15033.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15033/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15033"}},"corpus_meta":[{"pmid":"25752577","id":"PMC_25752577","title":"Assembly and specific recognition of k29- and k33-linked polyubiquitin.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25752577","citation_count":172,"is_preprint":false},{"pmid":"25723849","id":"PMC_25723849","title":"Assembly and structure of Lys33-linked polyubiquitin reveals distinct conformations.","date":"2015","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/25723849","citation_count":63,"is_preprint":false},{"pmid":"28356075","id":"PMC_28356075","title":"Genome-wide association study and accuracy of genomic prediction for teat number in Duroc pigs using genotyping-by-sequencing.","date":"2017","source":"Genetics, selection, evolution : GSE","url":"https://pubmed.ncbi.nlm.nih.gov/28356075","citation_count":43,"is_preprint":false},{"pmid":"23479728","id":"PMC_23479728","title":"Identification of a novel anti-apoptotic E3 ubiquitin ligase that ubiquitinates antagonists of inhibitor of apoptosis proteins SMAC, HtrA2, and ARTS.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23479728","citation_count":40,"is_preprint":false},{"pmid":"27162139","id":"PMC_27162139","title":"Ubiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4.","date":"2016","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27162139","citation_count":33,"is_preprint":false},{"pmid":"33607149","id":"PMC_33607149","title":"Exploring the \"Other\" subfamily of HECT E3-ligases for therapeutic intervention.","date":"2021","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33607149","citation_count":33,"is_preprint":false},{"pmid":"32151281","id":"PMC_32151281","title":"Epigenetic modulation of AREL1 and increased HLA expression in brains of multiple system atrophy patients.","date":"2020","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/32151281","citation_count":24,"is_preprint":false},{"pmid":"33313884","id":"PMC_33313884","title":"Insights from the genetic characterization of central precocious puberty associated with multiple anomalies.","date":"2021","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33313884","citation_count":21,"is_preprint":false},{"pmid":"34784951","id":"PMC_34784951","title":"Knockdown of circ-FURIN suppresses the proliferation and induces apoptosis of granular cells in polycystic ovary syndrome via miR-195-5p/BCL2 axis.","date":"2021","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/34784951","citation_count":20,"is_preprint":false},{"pmid":"37474493","id":"PMC_37474493","title":"IL-1β turnover by the UBE2L3 ubiquitin conjugating enzyme and HECT E3 ligases limits inflammation.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37474493","citation_count":19,"is_preprint":false},{"pmid":"31578312","id":"PMC_31578312","title":"KIAA0317 regulates pulmonary inflammation through SOCS2 degradation.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31578312","citation_count":18,"is_preprint":false},{"pmid":"31732561","id":"PMC_31732561","title":"Structural insights into a HECT-type E3 ligase AREL1 and its ubiquitination activities in vitro.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31732561","citation_count":14,"is_preprint":false},{"pmid":"25045014","id":"PMC_25045014","title":"A panel of protein markers for the early detection of lung cancer with bronchial brushing specimens.","date":"2014","source":"Cancer cytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/25045014","citation_count":14,"is_preprint":false},{"pmid":"39994458","id":"PMC_39994458","title":"Cross-ancestry genome-wide association study and systems-level integrative analyses implicate new risk genes and therapeutic targets for depression.","date":"2025","source":"Nature human behaviour","url":"https://pubmed.ncbi.nlm.nih.gov/39994458","citation_count":7,"is_preprint":false},{"pmid":"34584540","id":"PMC_34584540","title":"AREL1 E3 ubiquitin ligase inhibits TNF-induced necroptosis via the ubiquitination of MTX2.","date":"2021","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34584540","citation_count":6,"is_preprint":false},{"pmid":"27658114","id":"PMC_27658114","title":"Therapeutic targets in fibrotic pathways.","date":"2016","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/27658114","citation_count":6,"is_preprint":false},{"pmid":"37814452","id":"PMC_37814452","title":"Genome-wide association study using a single-step approach for teat number in Duroc, Landrace and Yorkshire pigs in Korea.","date":"2023","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37814452","citation_count":6,"is_preprint":false},{"pmid":"36003650","id":"PMC_36003650","title":"Downregulation of growth plate genes involved with the onset of femoral head separation in young broilers.","date":"2022","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36003650","citation_count":6,"is_preprint":false},{"pmid":"36938956","id":"PMC_36938956","title":"KIAA0317 regulates SOCS1 stability to ameliorate colonic inflammation.","date":"2023","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/36938956","citation_count":4,"is_preprint":false},{"pmid":"37522329","id":"PMC_37522329","title":"AREL1 resists the apoptosis induced by TGF-β by inhibiting SMAC in vascular endothelial cells.","date":"2023","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37522329","citation_count":4,"is_preprint":false},{"pmid":"39872979","id":"PMC_39872979","title":"Neuroinflammation mediates the progression of neonate hypoxia-ischemia brain damage to Alzheimer's disease: a bioinformatics and experimental study.","date":"2025","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/39872979","citation_count":2,"is_preprint":false},{"pmid":"41331534","id":"PMC_41331534","title":"E3 ligase AREL1 controls perinuclear localization of lysosomes and supports Purkinje cell survival.","date":"2025","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/41331534","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.06.02.25328820","title":"Whole-genome sequencing study of 488,888 individuals identifies rare variants and genes associated with glaucoma","date":"2025-06-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.02.25328820","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13688,"output_tokens":2237,"usd":0.03731},"stage2":{"model":"claude-opus-4-6","input_tokens":5567,"output_tokens":2462,"usd":0.134077},"total_usd":0.171387,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"AREL1 is a cytosolic HECT-family E3 ubiquitin ligase that interacts with and ubiquitinates IAP antagonists SMAC, HtrA2, and ARTS specifically after their release from mitochondria into the cytosol upon apoptotic stimulation, promoting their degradation and thereby inhibiting apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, knockdown/overexpression with apoptosis readouts (caspase-3 cleavage, XIAP degradation), subcellular fractionation/localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, functional ubiquitination assays, loss-of-function rescue with defined apoptosis readouts; original discovery paper\",\n      \"pmids\": [\"23479728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"AREL1 preferentially assembles K33- and K11-linked polyubiquitin chains in vitro, enabling large-scale production of K33-linked chains when combined with linkage-selective DUBs.\",\n      \"method\": \"In vitro ubiquitin chain assembly assay, mass spectrometry linkage analysis, combination with linkage-selective deubiquitinases\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with biochemical characterization; replicated in concurrent independent study (PMID:25752577)\",\n      \"pmids\": [\"25723849\", \"25752577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"AREL1 assembles K11/K33-linked polyubiquitin chains, while the related HECT E3 UBE3C assembles K48/K29-linked chains; K29- and K33-linked chains adopt open/dynamic and distinct conformations respectively.\",\n      \"method\": \"In vitro ubiquitin chain assembly, mass spectrometry, NMR solution studies, crystal structure of K33-linked diUb\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution, structural analysis, replicated by PMID:25723849\",\n      \"pmids\": [\"25752577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The crystal structure of the extended HECT domain of AREL1 (aa 436–823) at 2.4 Å reveals an inverted T-shaped bilobed conformation with a unique loop (aa 567–573) absent in other HECT members; the N-terminal extended region (aa 436–482) preceding the HECT domain is essential for stability and catalytic activity. AREL1 ubiquitinates SMAC primarily on Lys62 and Lys191, and assembles K33-, K48-, and K63-linked polyubiquitin chains. E701A substitution increases auto- and SMAC-ubiquitination activity, while deletion of the C-terminal three residues abolishes autoubiquitination and reduces SMAC ubiquitination.\",\n      \"method\": \"X-ray crystallography (2.4 Å HECT domain; 2.8 Å tetrameric SMAC), in vitro ubiquitination assay, active-site mutagenesis, ubiquitin variant inhibitor\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures plus in vitro reconstitution and mutagenesis in single study\",\n      \"pmids\": [\"31732561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AREL1 interacts with Metaxin 2 (MTX2) via the carboxyl-terminal domain of MTX2, ubiquitinates MTX2, and promotes its degradation, thereby inhibiting TNF-induced necroptosis; the catalytically dead AREL1-C790A mutant fails to degrade MTX2.\",\n      \"method\": \"Co-immunoprecipitation (domain mapping), overexpression/knockdown, catalytic mutant (C790A), necroptosis assay\",\n      \"journal\": \"Experimental and therapeutic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP with domain mapping and catalytic mutant, single lab\",\n      \"pmids\": [\"34584540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AREL1, together with TRIP12, adds destabilizing K27-, K29-, and K33-linked polyubiquitin chains onto pro-IL-1β, promoting its proteasomal disposal and thereby limiting mature IL-1β production and neutrophilic inflammation; UBE2L3 acts as the cognate E2 enzyme in this process.\",\n      \"method\": \"Unbiased RNAi screen, in vivo Ube2l3 knockout mouse model, ubiquitin linkage analysis, macrophage pro-IL-1β turnover assay, inflammasome activation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased RNAi screen identifying AREL1, in vivo KO model, linkage-specific ubiquitination characterization; multiple orthogonal methods\",\n      \"pmids\": [\"37474493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AREL1 interacts with SMAC in TGF-β-treated HUVECs and its overexpression inhibits TGF-β-induced apoptosis by downregulating SMAC, suppressing caspase-3 and caspase-9 activation; miR-320b negatively regulates AREL1 expression.\",\n      \"method\": \"Co-immunoprecipitation, overexpression, caspase activity assay, miRNA mimics/inhibitors\",\n      \"journal\": \"Journal of biochemical and molecular toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP with functional OE data, single lab\",\n      \"pmids\": [\"37522329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"AREL1, localized to the ER, establishes membrane contacts with lysosomes by directly binding the Voa subunit of V-ATPase and catalyzes K33-linked polyubiquitylation of the V-ATPase V1B2 subunit, inducing its interaction with UBAC2 at the perinuclear ER, thereby promoting perinuclear lysosome positioning. Loss of AREL1 increases peripheral lysosomes with partially assembled V-ATPase, elevated luminal pH, and reduced degradative capacity; Arel1-knockout mice exhibit age-dependent Purkinje cell loss, ataxia, and lipofuscin accumulation indicating lysosomal dysfunction.\",\n      \"method\": \"Co-IP (Voa binding), in vitro/cell-based K33-ubiquitination assay, live-cell imaging (lysosome positioning), lysosomal pH measurement, Arel1-/- knockout mouse with behavioral/histological phenotyping, ZRANB1 (DUB) epistasis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including direct interaction, ubiquitination assay, live imaging, in vivo knockout, DUB epistasis in single rigorous study\",\n      \"pmids\": [\"41331534\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AREL1 is an ER-resident HECT E3 ubiquitin ligase that preferentially assembles atypical K11-, K33-linked (and also K27-, K29-) polyubiquitin chains on substrates including IAP antagonists (SMAC, HtrA2, ARTS), MTX2, pro-IL-1β, and the V-ATPase V1B2 subunit, functioning as an anti-apoptotic and anti-necroptotic regulator, a limiter of IL-1β-driven inflammation, and a controller of perinuclear lysosome positioning and acidification through an AREL1–UBAC2–V-ATPase axis, with loss of AREL1 in mice causing lysosomal dysfunction and Purkinje cell neurodegeneration.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"AREL1 is a HECT-family E3 ubiquitin ligase that assembles atypical polyubiquitin chains—predominantly K33- and K11-linked, but also K27-, K29-, K48-, and K63-linked—to regulate apoptosis, necroptosis, inflammation, and lysosomal homeostasis [PMID:25723849, PMID:25752577, PMID:31732561]. AREL1 ubiquitinates and promotes proteasomal degradation of the mitochondrial IAP antagonists SMAC, HtrA2, and ARTS following their cytosolic release during apoptosis, thereby suppressing caspase activation and cell death; it similarly ubiquitinates Metaxin 2 to inhibit TNF-induced necroptosis and cooperates with TRIP12 and the E2 UBE2L3 to attach K27/K29/K33-linked chains to pro-IL-1β, limiting inflammasome-driven inflammation [PMID:23479728, PMID:34584540, PMID:37474493]. Localized to the endoplasmic reticulum, AREL1 directly binds the V-ATPase Voa subunit and catalyzes K33-linked polyubiquitylation of the V1B2 subunit, which recruits UBAC2 at perinuclear ER–lysosome contact sites to control lysosome positioning and acidification; Arel1-knockout mice develop age-dependent Purkinje cell neurodegeneration, ataxia, and lipofuscin accumulation consistent with lysosomal dysfunction [PMID:41331534].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Establishing AREL1 as a HECT E3 ligase with anti-apoptotic function resolved how cytosolic IAP antagonists (SMAC, HtrA2, ARTS) are cleared after mitochondrial release, identifying a previously unknown ubiquitin-dependent brake on apoptosis.\",\n      \"evidence\": \"Co-immunoprecipitation, ubiquitination assays, knockdown/overexpression with caspase-3 and XIAP readouts in mammalian cells\",\n      \"pmids\": [\"23479728\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Ubiquitin chain linkage specificity on substrates was not determined\",\n        \"In vivo physiological relevance of AREL1-mediated IAP antagonist degradation was not tested\",\n        \"Structural basis for substrate recognition was unknown\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining AREL1's preference for K33- and K11-linked polyubiquitin chains in vitro placed it among the rare E3 ligases generating atypical ubiquitin linkages, raising questions about the signaling roles of these chains beyond canonical proteasomal targeting.\",\n      \"evidence\": \"In vitro chain assembly, mass spectrometry linkage quantification, NMR solution studies, and crystal structure of K33-linked diUb by two independent laboratories\",\n      \"pmids\": [\"25723849\", \"25752577\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether K33/K11 linkage preference holds on physiological substrates in cells was untested\",\n        \"No reader/decoder protein for K33-linked chains was identified\",\n        \"Structural basis of AREL1 HECT domain linkage selectivity was unresolved\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The crystal structure of AREL1's extended HECT domain revealed an inverted T-shaped architecture with a unique loop and showed that N-terminal extension and C-terminal integrity are required for catalysis, providing the first structural framework for understanding its activity and regulation.\",\n      \"evidence\": \"X-ray crystallography at 2.4 Å, site-directed mutagenesis (E701A, C-terminal deletion), in vitro ubiquitination of SMAC with mapped sites (K62, K191)\",\n      \"pmids\": [\"31732561\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structure of AREL1 bound to substrate or E2 was not obtained\",\n        \"Mechanism by which the unique loop (aa 567–573) contributes to function was unclear\",\n        \"Chain linkage selectivity determinants were not structurally resolved\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrating that AREL1 ubiquitinates and degrades Metaxin 2 to inhibit TNF-induced necroptosis expanded its functional scope beyond apoptosis to a second cell-death modality.\",\n      \"evidence\": \"Co-immunoprecipitation with domain mapping, catalytic-dead C790A mutant, necroptosis assay in mammalian cells\",\n      \"pmids\": [\"34584540\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-laboratory finding without independent replication\",\n        \"Ubiquitin chain type on MTX2 was not characterized\",\n        \"In vivo relevance of AREL1–MTX2 axis in necroptotic disease was not tested\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"An unbiased RNAi screen identified AREL1 (with TRIP12 and the E2 UBE2L3) as a key ubiquitin ligase attaching K27/K29/K33-linked chains to pro-IL-1β, revealing a ubiquitin-dependent mechanism that limits inflammasome-driven inflammation independently of cell death.\",\n      \"evidence\": \"Genome-wide RNAi screen, Ube2l3 knockout mouse, ubiquitin linkage mass spectrometry, macrophage pro-IL-1β turnover and inflammasome activation assays\",\n      \"pmids\": [\"37474493\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative contributions of AREL1 versus TRIP12 to pro-IL-1β turnover were not fully dissected\",\n        \"Whether K33-linked chains are decoded by a specific ubiquitin-binding domain protein for pro-IL-1β disposal was unknown\",\n        \"Tissue-specific roles in inflammation in vivo were not resolved\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Localizing AREL1 to the ER and showing it forms ER–lysosome contacts via V-ATPase Voa binding and K33-ubiquitylates V1B2 to recruit UBAC2 for perinuclear lysosome positioning fundamentally reframed AREL1 as a spatial organizer of lysosomal function, with knockout mice exhibiting Purkinje cell neurodegeneration and lysosomal dysfunction.\",\n      \"evidence\": \"Co-IP of Voa interaction, in vitro and cell-based K33-ubiquitination assays, live-cell lysosome imaging, pH measurements, Arel1−/− mouse behavioral/histological phenotyping, ZRANB1 DUB epistasis\",\n      \"pmids\": [\"41331534\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether the lysosomal phenotype fully explains the neurodegeneration or other substrates contribute was not resolved\",\n        \"Human genetic disease association has not been established\",\n        \"Structural basis of AREL1–Voa interaction at ER–lysosome contacts is unknown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How AREL1's diverse substrate activities—anti-apoptotic IAP antagonist degradation, anti-necroptotic MTX2 degradation, pro-IL-1β disposal, and V-ATPase-dependent lysosome positioning—are coordinated in different cellular contexts, and whether K33-linked chains serve as a unifying signal decoded by specific reader proteins, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No K33-chain reader/decoder protein has been definitively identified beyond UBAC2\",\n        \"Tissue- and stimulus-specific regulation of AREL1 substrate selection is unknown\",\n        \"Full-length AREL1 structure with substrate and E2 has not been determined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 5, 7]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [0, 1, 3, 5, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 4, 6]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 3, 5, 7]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"DIABLO\",\n      \"HTRA2\",\n      \"ARTS\",\n      \"MTX2\",\n      \"TRIP12\",\n      \"UBE2L3\",\n      \"ATP6V1B2\",\n      \"UBAC2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}